**New indications List**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **No** | **Date of approval** | **Product name** | **MAH** | **Active ingredient** | **The new Indication** |
| 1. | 17/11/2020 | Opdivo 100mg/10ml & 40mg/4ml solution for infusion | Bristol myers | Nivolumab | small cell lung cancer |
| 2. | 17/11/2020 | Yervoy 200mg/40ml & 50mg/10ml solution for infusion | Bristol myers | Ipilimumab | 1. NSCLC, 2. Hepatocellular carcinoma, 3. Rectal carcinoma |
| 3. | 19/11/2020 | Visipaque 270mgI/ml & 320mgI/ml solution for infusion | GE healthcare AS | Iodixanol | 1. Gastrointestinal tract studies 2. Arthrography and Hysterosalpingography (HSG) |
| 4. | 20/12/2020 | Tecentriq 1200mg/20ml concentrate for solution for infusion | F.Hoffmann La- Roche | Atezolizumab | 1. Non-small cell lung cancer 2. Small cell lung cancer |
| 5. | 24/12/2020 | Glypressin 1mg/8.5 ml solution for injection | Ferring | Terlipressin | Hepatorenal Syndrome |
| 6. | 08/08/2021 | Keytruda 100 mg / 4 ml Infusion Vial | Merck Sharp & Dohme Corp | Pembrolizumab | Treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.  In combination with lenvatinib, is indicated for the treatment of patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.  This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. |
| 7. | 30/08/2021 | Forxiga 5 & 10mg FC tablets | AstraZeneca/ UK | Dapagliflozin | Treatment of symptomatic chronic heart failure with reduced ejection fraction |
| 8. | 07/12/2021 | Jardiance 10 mg & 25 mg Tablets | Boehringer Ingelheim International/ Germany | Empagliflozin | Heart Failure: Jardiance is used to treat heart failure in adult patients with symptoms due to  a weak pump function of the heart |
| 9. | 17/4/2022 | Opdivo 40mg/4ml & 100mg/10ml Solution for IV infusion | Bristol Myers Squibb Company /USA | Nivolumab | -malignant pleural mesothelioma  - Gastric Cancer, Gastro esophageal Junction Cancer, and Esophageal Adenocarcinoma  - Adjuvant Esophageal Cancer  - metastatic esophageal squamous cell carcinoma |
| 10. | 18/09/2022 | Yervoy ( 50mg/10ml ) injection for solution for infusion | Bristol Myers Squibb/USA | Ipilimumab | Malignant pleural Mesothelioma : in combination with Nivolumab as first line treatment of adult with unresectable Malignant pleural Mesothelioma |
| 11. | 7/11/2022 | Xeljanz 5mg Tablets | Pfizer Inc /USA | Tofacitinib | Polyarticular course Juvenile Idiopathic Arthritis in patient 2 years age and older |
| 12. | 12/01/2023 | Beovu 120mg/ml solution for injection PFS | Novartis Europharm Limited/Ireland | brolucizumab | Diabetic macular oedema |
| 13. | 27/02/2023 | Tecentriq 1200mg/20ml concentrate for solution for infusion | F.Hoffmann La- Roche | Atezolizumab | Hepatocellular |
| 14. | 26/4/2023 | Cosentyx 150 mg/ml PFS & PFP auto injector | Novartis Pharma AG/Switzerland | Secukinumab | Juvenile idiopathic arthritis, including enthesitis-related arthritis and juvenile psoriatic arthritis  in patients (6 years of age and older) |
| 15. | 11/5/2023 | Kyprolis 60 mg vial  Powder for Solution for Injection | Onyx/USA | Carfilzomib | the treatment of adult patients with relapsed or refractory multiple myeloma  who have received one to three lines of therapy  in combination with Daratumumab and hyaluronidase-fihj and dexamethasone |
| 16 | 28/5/2023 | Keytruda 100 mg / 4 ml Infusion Vial | Merck Sharp & Dohme Corp  /USA | Pembrolizumab | Non-Small Cell Lung Cancer as a single agent, is indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. |
| 17 | 20/8/2023 | Cosentyx 150 mg/ml PFS & PFP auto injector | Novartis Pharma AG/Switzerland | Secukinumab | in adults with hidradenitis suppurativa (acne inversa or Verneuil’s disease) If they do not respond well to other medicines |
| 18 | 28/9/2023 | Lynparza 100 & 150 mg tablets | Astrazeneca UK Limited / UK | Olaparib | 1. Adjuvant Treatment of Germline BRCA-mutated HER2-negative High Risk Early Breast Cancer. 2. Treatment of BRCA-mutated Metastatic Castration-Resistant Prostate Cancer in Combination with Abiraterone and Prednisone or Prednisolone. |
| 19 | 29/10/2023 | Jardiance 10 mg & 25 mg Tablets | Boehringer Ingelheim / Germany | Empagliflozin | Chronic kidney disease |
| 20 | 09/04/2023 | Yervoy (50mg/10ml) injection for solution for infusion | Bristol Myers Squibb/USA | Ipilimumab | First line treatment of unresectable advanced or metastatic ESCC |
| 21 | 04/03/2024 | Opdivo 40mg/4ml & 100mg/10ml Injection | Bristol Myers Squibb/USA | Nivolumab | * Adjuvant treatment of urothelial carcinoma * Neoadjuvant treatment of resectable NSCLC Indication |
| 22 | 13/03/2024 | Zoladex LA 10.8mg Implant in PFS | AstraZeneca UK Ltd / UK | Goserelin | Indicated in the management of oestrogen receptor (ER) early and advanced breast cancer in pre and peri menopausal women |
| 23 | 06/05/2024 | Pulmicort 0.5 mg/ml Nebulizer Suspension | AstraZeneca A.B. /Sweden | Budesonide | Exacerbation of chronic COPD in persons without signs of acute respiratory insufficiency. |
| 24 | 06/05/2024 | Pulmicort 0.5 mg/ml Nebulizer Suspension | AstraZeneca A.B. /Sweden | Budesonide | Very severe pseudocroup in which hospitalization is indicated. |
| 25 | 01/09/2024 | Imfinzi | AstraZeneca Ltd/UK | Durvalumab | * Biliary track cancer * Unresectable hepatocellular carcinoma (uHCC). |
| 26 | 9/9/2024 | Xeljanz 5mg Tablets | Pfizer Inc /USA | Tofacitinib | * ankylosing spondylitis |
| 27 | 26/9/2024 | Enhertu | AstraZeneca UK limited /UK | (trastuzumab deruxtecan) | * Non-Small cell lung cancer |

**Note:** If you have any objection please don’t hesitate to contact us

**Registration Department Drug Directorate**

** Jordan Food & Drug Administration**